Isofol Medical

The information in the press release is intended for investors.

Isofol’s CEO Petter Segelman Lindqvist will present Isofol and the drug candidate arfolitixorin, which is being developed as a new adjunct treatment for severe forms of cancer. The company is preparing to initiate a clinical phase Ib/II study in metastatic colorectal cancer, and the latest developments will be presented at:

March 5 – Life Science-dagen in Gothenburg, Sweden
Isofol will present at 11:45 CET (in Swedish), and the event will be available online.
www.lifesciencedagen.se

March 13 – Swiss Nordic Bio in Zürich, Switzerland
www.swissnordicbio.com

June 16–19 – BIO International Convention in Boston, U.S.
https://convention.bio.org

Additional meetings and events will be announced as they are scheduled.

For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer 
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56

The information was submitted for publication, through the agency of the contact person set out above, at 07:45 CET, on March 5, 2025.

About Isofol Medical AB (publ)
Isofol Medical AB (publ) works to improve the prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the efficacy of first-line standard treatments for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with new dosage regimens that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com